Dr Graham Wylie, Founder and Executive Chairman of MRN, has been named as one of The LDC Top 50 Most Ambitious Business Leaders for 2022.
The program, which is supported by The Times and now in its fifth year, celebrates the inspiring leaders behind some of the UK’s most successful and fast-growing medium-sized firms.
A record number of nominations – more than 750 – were received this year, proving that ambition is alive and well despite the challenges faced by increasing economic uncertainty.
The business leaders featured in The Top 50 demonstrate resilience, strategic excellence and export success. They operate across a broad range of sectors and are driving growth in every corner of the UK – from Edinburgh to Brighton, and Bath to Norfolk. Collectively, they employ almost 9,500 people and turn over more than £1.2 billion.
Under Graham’s leadership, MRN have been the pioneers of decentralizing clinical trials for the Pharmaceutical Industry first bringing their solutions to the market in 2006. MRN’s ethos of innovation and continuous improvement have kept it at the forefront of quality trial delivery, patient care, and the introduction of new clinical and digital elements of decentralized clinical trials that make trials run more efficiently. MRN is now the largest international provider of specialist community-based clinical trial delivery, helping patients participate in trials while remaining in their homes. MRN has offices in the UK, Spain, Germany, USA, and Japan and provides local home trial services across all major clinical research countries spanning North America, Latin America, Europe, Asia, and Australasia.
Dr Graham Wylie, Founder and Executive Chairman of MRN said: “It is an honor to be named one of UK’s Top 50 most ambitious business leaders. From inception, our goal has been to create a business that does what is best for patients, driving the industry toward more patient-centric trial design while getting important drugs to the market faster. To date, we have delivered well over 80,000 decentralized visits to patients and have masterfully combined clinical and digital elements for the most comprehensive decentralized capabilities, giving patients greater access to participation and clients better run trials. Given the ambition of everyone within our business, there is no limit to what we can accomplish”
John Garner, Managing Partner, LDC, added: “The volume and quality of submissions this year surpassed all of our expectations. We’ve been struck by the way business leaders have overcome challenges and adversity to run fast-growing and successful companies, proving that difficult circumstances can become the biggest driver of ambition. There are so many fascinating stories behind each and every business leader in this year’s Top 50 and I’d like to congratulate all of those featured. We look forward to seeing where they go next!”
You can find out more information on this year’s Top 50 Most Ambitious Business Leaders program here: https://bit.ly/3EiQ6V9
At MRN we understand the complexities of today’s clinical trial environment and the burden placed on patients, clients, and sites. Our services are designed to ease these burdens, from community researchers, digital technology deployment, through to investigator site professional support; accelerating patient recruitment and retention with improved data quality. We work to maximize the efficiency of clinical trials for drug developers, by improving the patient’s experience, no matter where their community is in the world.
LDC is the private equity arm of Lloyds Banking Group. Since 1981, LDC has invested more than £5.5bn in medium-sized firms across the UK; backing the ambitions of more than 650 ambitious management teams.
Medical Research Network
Vice President Commercial Development